Advancing Treatment of Disease with Innovative protein therapeutics and Technologies

Targeted treatment against chronic hepatitis C infection

TBI 301 is a hemoglobin-conjugated ribavirin (RBV) compound designed to target RBV to the liver. Ribavirin is an antiviral drug that constitutes the current standard of care1,2, in combination with PEGylated interferon-α (PEG-IFNα), for the treatment of chronic hepatitis C virus (HCV) infection.

Targeted delivery of ribavirin with TBI 301 is designed to overcome some of the major limitations to RBV treatment that relate to both efficacy and safety:

  • Only 50% of patients achieve a sustained virologic response with standard treatment3
  • Severe side effects have been associated with RBV treatment

TBI 301 may fill an important unmet medical need in patients infected with HCV by allowing for increased drug concentration specifically in the liver while limiting systemic exposure to RBV.

To learn more about the pre-clinical drug research on TBI 301, please refer to an article by Levy and colleagues.

REFERENCES

  1. Poordad F, Dieterich D. Current Standard of Care and Emerging Direct-acting Antiviral Agents. J Viral Hepat. 2012; 10(7):449-64.
  2. Kanda T, Yokosuka O, Omata M. Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine 2013;2(9):1-8.
  3. Centers for Disease Control and Prevention. Chapter 3 Infectious Diseases Related To Travel. Available here. Accessed Aug 14, 2013.

To learn more about our areas of research, platform technologies and pipeline products, or to explore opportunities to partner and/or collaborate with us to improve existing therapeutics, please contact us at innovations@therapurebio.com.